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Background. Human immunodeﬁciency virus (HIV)–infected people who inject drugs (PWID) frequently encounter barriers
accessing and remaining on antiretroviral therapy (ART). Some studies have suggested that opioid substitution therapy (OST) could
facilitate PWID’s engagement with HIV services. We conducted a systematic review and meta-analysis to evaluate the impact of
concurrent OST use on ART-related outcomes among HIV-infected PWID.
Methods. We searched Medline, PsycInfo, Embase, Global Health, Cochrane, Web of Science, and Social Policy and Practice
databases for studies between 1996 to November 2014 documenting the impact of OST, compared to no OST, on ART outcomes.
Outcomes considered were coverage and recruitment onto ART, adherence, viral suppression, attrition from ART, and mortality.
Meta-analyses were conducted using random-effects modeling, and heterogeneity assessed using Cochran Q test and I2 statistic.
Results. We identiﬁed 4685 articles, and 32 studies conducted in North America, Europe, Indonesia, and China were included.
OST was associated with a 69% increase in recruitment onto ART (hazard ratio [HR], 1.69; 95% conﬁdence interval [CI], 1.32–2.15),
a 54% increase in ART coverage (odds ratio [OR], 1.54; 95% CI, 1.17–2.03), a 2-fold increase in adherence (OR, 2.14; 95% CI, 1.41–
3.26), and a 23% decrease in the odds of attrition (OR, 0.77; 95% CI, .63–.95). OST was associated with a 45% increase in odds of viral
suppression (OR, 1.45; 95% CI, 1.21–1.73), but there was limited evidence from 6 studies for OST decreasing mortality for PWID on
ART (HR, 0.91; 95% CI, .65–1.25).
Conclusions. These ﬁndings support the use of OST, and its integration with HIV services, to improve the HIV treatment and
care continuum among HIV-infected PWID.
Keywords. HIV; people who inject drugs (PWID); medication-assisted therapy for opioid dependence (MAT); antiretroviral
treatment (ART); systematic review.
Although harm reduction programs for people who inject drugs
(PWID) are being scaled up globally, coverage remains low
[1, 2].Approximately 30% of new infections outside sub-Saharan
Africa are attributed to injecting drug use [3], and the epidemic is
growing in Central Asia and Eastern Europe [4, 5]. In recent
years, increased injecting drug use has been documented in sev-
eral countries with high human immunodeﬁciency virus (HIV)
prevalence, such as Kenya and Tanzania [6, 7], and new HIV out-
breaks have occurred in PWID in other settings, including the
United States [8, 9].
Worldwide, new goals of achieving high coverage of HIV test-
ing, treatment, and viral suppression have been proposed, with
the aim of dramatically reducing global HIV transmission and
morbidity [10].However, PWID often have poor HIV treatment
coverage [1, 11] and antiretroviral therapy (ART) outcomes
[12, 13], which could hamper progress toward these goals. To
achieve these targets in this group, interventions are needed
to improve treatment outcomes. One such intervention could
be opioid substitution therapy (OST), also known as medica-
tion-assisted therapy for opioid dependence (MAT), which
could potentially enhance the uptake and retention of PWID
on ART [14], their adherence to ART [15], and possibly their
treatment outcomes [16].
To synthesize available evidence, we conducted a systematic
review and meta-analysis to quantify the impact of concurrent
OST use on the following ART outcomes among PWID: re-
cruitment onto ART, adherence to ART, viral suppression
and immune recovery, attrition from ART, individual mortality,
and coverage at the programmatic level.
METHODS
Search Strategy
A systematic literature search was performed. The search iden-
tiﬁed studies describing the impact of OST on ART outcomes
Received 17 February 2016; accepted 15 June 2016; published online 25 June 2016.
Correspondence: A. J. Low, Mailman School of Public Health, Columbia University, 722 W
168th, 13th Flr, New York, NY 10032 (andrea_low@hotmail.com).
Clinical Infectious Diseases® 2016;63(8):1094–104
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of
America. This is an Open Access article distributed under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/
4.0/), which permits non-commercial reproduction and distribution of the work, in any
medium, provided the original work is not altered or transformed in any way, and that the
work is properly cited. For commercial re-use, contact journals.permissions@oup.com.
DOI: 10.1093/cid/ciw416
1094 • CID 2016:63 (15 October) • HIV/AIDS
(search 1), and studies of PWID taking ART regardless of
whether OST status was mentioned in the title or abstract
(search 2). We searched Medline, Global Health, Embase, Social
Policy and Practice, the Cochrane Library, and Web of Science
including conference proceedings, from 1996 to November
2014 (see Supplementary Appendix 1 for search terms). We in-
cluded experimental and observational studies that drew on
quantitative methods, without any language or sample size re-
strictions. For additional sources, reference lists were screened,
and known cohorts of PWID and corresponding author names
were searched in Google Scholar.
Study Deﬁnitions and Outcomes
Interventions of Study
OST or MAT includes psychoactive medications administered
under supervision with the aim of reducing opioid dependence
and withdrawal symptoms; opioid agonists include methadone
(methadone maintenance therapy), and buprenorphine; antag-
onists include naloxone or naltrexone. Older agents include co-
deine, levo-α-acetylmethadol, and morphine. ART was deﬁned
as highly active or combined HIV treatment, including ≥3
agents.
Study Outcomes
The primary outcome was the impact of OST in PWID on each
step of the HIV treatment and care continuum following diag-
nosis [17, 18]. The primary outcomes are as follows: (1) ART
coverage is the proportion of eligible HIV-infected PWID
prescribed ART at a ﬁxed point in time, and recruitment is
the cumulative proportion who initiated ART during follow-
up; (2) adherence to ART is the proportion of PWID on ART
achieving a deﬁned threshold of ART adherence, whether self-
reported or objectively measured; (3) viral suppression is the
proportion of those on ART with undetectable plasma HIV
viral loads, based on the threshold of detection in each study
(<500, <400 or <50 copies/mL); (4) CD4 count response to
ART is the median or mean CD4 cell count increase over
time on ART; (5) attrition from ART is the proportion of
those on ART who were lost to follow-up or discontinued
ART during follow-up, excluding those who died if data was
available; and (6) mortality rate on ART is the HIV-related
mortality rate during follow-up or, if this was not available,
all-cause mortality rate.
Inclusion Criteria
Included studies presented outcomes of interest in adult (>15
years old) PWID populations where data were available to com-
pare outcomes for PWID receiving OST to those not receiving
OST. All studies describing active or former PWID were includ-
ed, but, when available, data for active PWID were preferentially
used (Table 1). Active PWID were those who injected drugs
within a deﬁned recent time period, as described in the studies.
Studies of monotherapy or dual ART were excluded because
of their limited relevance. We excluded review papers, modeling
studies, commentaries, or editorials without primary data, but
their reference lists were screened for additional sources. Studies
describing substance abuse support, harm reduction services, or
other forms of therapy without including OST as a core compo-
nent were excluded. Studies were also excluded if the majority of
drug users had never injected illicit drugs, or were only crack
cocaine, alcohol, or methamphetamine users and therefore
not eligible for OST.
Duplicate references were removed. Two reviewers conducted
the search, screened titles and abstracts, and reviewed full-text
articles or conference posters for inclusion. Disagreements on
study eligibility were resolved with P. V., M. T. M., and
N. J. W. Data were extracted from selected articles, including
study design, recruitment methodology, outcome measure-
ment, years of study, follow-up time and months of ART, num-
ber of participants, and measures of effect with 95% conﬁdence
intervals (CIs) where available. If not reported, CIs were calcu-
lated from raw data.
Data Analysis
Search results were summarized for each outcome, including
the number of studies and separate cohorts represented.
Where there were multiple publications from the same study
or cohort for the same outcome, we included the most compre-
hensive in the meta-analysis, as deﬁned by number of partici-
pants, years covered, and comparability of outcome measure
with other studies, to minimize bias [19]. The proportion of
women in each study was stratiﬁed as <25% or ≥25%. Geo-
graphical region was deﬁned as North America, Europe, or
Asia. For studies that did not report the ﬁnal year of measure-
ment, it was assumed to be 2 years before publication.
To provide a summary estimate for each outcome by OST
status, crude odds ratios (ORs) or hazard ratios (HRs) and
their standard error were log-transformed. Adjusted estimates
were also pooled and the effect size compared to the pooled
crude estimate. Outcomes were summarized using the predom-
inant type of effect estimate (OR or HR), with conversion of dif-
fering estimates to maintain consistency when data allowed
(Supplementary Appendix 2). Increases in CD4 counts were
pooled using standardized mean difference (SMD) using the
Hedges g adjustment, to account for the large variation in
scale of measurement across studies [20].Where studies report-
ed a proportion with a predeﬁned increase in CD4 count, the
proportion was converted to an SMD by assuming a logistic dis-
tribution for CD4 counts, so that the SMD was estimated by
multiplying the log OR and its standard error by √3/π [21].
Summary effect measures were obtained using random-
effects meta-analysis, as we expected high between-study vari-
ability. Between-study heterogeneity was evaluated using the I2
statistic and the P value for heterogeneity (Cochran Q statistic)
[22]. For outcomes with data from ≥10 studies and high levels
of heterogeneity, we performed random-effects meta-regression
HIV/AIDS • CID 2016:63 (15 October) • 1095
Table 1. Characteristics of Included Studies and Reported Outcomes
Author and Year
Study
Perioda
Location
(City, Country)
Cohort: Recruitment Site and
Method, Inclusion Criteria
No. on OST/
Total (no./No.)
Type of
OST
Comparison
Population
Median
Follow-
up, mo
ART
Outcomes
Abellan 1999 1997–1998 Madrid, Spain NS: People infected through
IDU starting PI-containing
ART
18/28 MMT Active IDU at
baseline
4 VL CD4
Achmad 2009 2006–2009 West Java,
Indonesia
Hospital clinic recruitment
Age >18, ICD-9 OD in
previous 12 mo, attempt to
stop opioids at least once
25/140 MMT Former IDU
starting ART,
matched for
date of ART
initiation
14 VL AT MO
Altice 2011 2004–2009 10 sites, USA BHIVES cohort: Provider
referral, word of mouth,
community outreach
Age >18, DSM-IV OD,
excluded for alcohol or
benzodiazepine abuse,
mental illness or increased
AST/ALT, pregnant
84/266 BUP/NX PWID not retained
on BUP/NX
12 Cov UP
VL CD4
Celentano 1998 1996–1997 Baltimore, USA ALIVE cohort: Drug abuse
treatment centers, STD &
HIV clinics, parole officers,
street outreach
Age >18, injected drugs
between 1977 and study
entry, CD4 count < 500 in
1996
97/404 MMT Not in drug
treatment in
past 6 mo. 52%
overall current
drug use
CS Cov
Celentano 2001 1996–1999 Baltimore, USA ALIVE cohort: Drug abuse
treatment centers, STD &
HIV clinics, parole officers,
street outreach
Age >18, injected drugs
within past 10 y
115/528 MMT PWID abstinent
from IDU
42 UP
Escaffre 2000 1996–1998 Marseilles,
Nice, and
Paris, France
MANIF 2000 cohort: Hospital
clinic recruitment
Age >18, infected through
injecting drug use
145/429 BUP Not in DMT, 48%
IDU in past 6 mo
overall
CS Cov
Kapadia 2008 1998–2002 6 sites, USA WIHS cohort: Clinic referrals,
community outreach,
participant word of mouth
Women who had engaged in
drug use at baseline or
during follow-up on ART
74/136 MMT No current MMT 60 AD
Kavasery 2009 1996–2006 Baltimore, USA ALIVE cohort: Drug abuse
treatment centers, STD &
HIV clinics, parole officers,
street outreach
Age >18, injected drugs
between 1977 and study
entry, AIDS-free at
enrollment
82/269 MMT No MMT and no
IDU in past 6 mo
31 AT
Kerr 2005 2001–2002 Vancouver,
Canada
VIDUS cohort: Self-referral,
street outreach
Age >18, illicit drug use in
past month, reside in
Vancouver region, had
taken or were taking ART
78/160 MMT No MMT in past 6
mo
CS AT
Knowlton 2010 2001–2005 4 sites, USA INSPIRE cohort: Community
venues, shelters, medical
clinics and methadone
clinics Injected drugs in
past year, heterosexual act
in past 3 mo
223/1225 MMT No current
methadone
treatment
6 Cov AT
Lucas 2006 2001–2003 Baltimore, USA Methadone clinics, HIV care
provider referral
Age >18, baseline HIV-1
RNA > 500 copies/mL, no
triple-class drug resistance
75/319 MMT PWID not receiving
MMT at time of
ART initiation
6
12
VL CD4
Michel 2009 1996–2003 Marseilles,
Nice, and
Paris, France
MANIF 2000 cohort: Hospital
clinic recruitment
Age >18, infected through
injecting drug use
100/294 Both Not on OST; 92%
abstinent in the
prior 6 mo
48 MO
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Table 1 continued.
Author and Year
Study
Perioda
Location
(City, Country)
Cohort: Recruitment Site and
Method, Inclusion Criteria
No. on OST/
Total (no./No.)
Type of
OST
Comparison
Population
Median
Follow-
up, mo
ART
Outcomes
Moatti 2000 1995–1998 Marseilles,
Nice, and
Paris, France
MANIF 2000 cohort: Hospital
clinic recruitment
Age >18, infected through
injecting drug use, CD4
count > 300 in visit before
enrollment, no OIs
32/51 BUP Active IDU in past
6 mo, not on
BUP at baseline
CS AD
Palepu 2006 1996–2003 Vancouver,
Canada
VIDUS cohort: Self-referral,
street outreach
Age >18, illicit drug use in
past month, reside in
Vancouver region; 25%
weekly heroin use at
baseline
161/278 MMT Not on MMT 58 AD VL
CD4
Reddon 2014 1996–2008 Vancouver,
Canada
ACCESS cohort: Self-referral,
street outreach
Age >18, illicit drug use other
than cannabinoids in past
month, on ART during
study period
198/408 MMT Not on MMT in
past 6 mo
15 AT
Richardson
2014
1996–2010 Vancouver,
Canada
ACCESS cohort: Self-referral,
street outreach
Age >18, illicit drug use other
than cannabinoids in past
month; 90% with IDU in
past 6 mo overall
186/666 MMT No MMT in past 6
mo
51 MO
Roux 2009 1995–2007 Marseilles,
Nice, and
Paris, France
MANIF 2000: Hospital clinic
recruitment
Age >18, infected through
injecting drug use, on ART
for ≥6 mo, OD during study
80/153 Both No OST in previous
6 mo
24 VL
Sambamoorthi
2000
1996 New Jersey,
USA
Surveillance data of Medicaid
records for PWID with drug
abuse claims
Age >18, AIDS diagnosis;
receiving Medicaid
services for >90 d
276/1109 MMT Current drug use
based on ICD-9
codes
CS Cov
Schinkel 1998 1996–1997 Amsterdam,
The
Netherlands
ACSA cohort: At methadone
posts and STD clinics
PWID with CD4 count < 500
starting PI-based ART
97/103 MMT Not on MMT;
active drug use
in past 6 mo at
the last visit in
75% overall
CS Cov
Springer 2012 2005–2010 Connecticut,
USA
Prisoners transitioning to the
community
Age >18, DSM-IV OD,
returning to New Haven or
Hartford, not pregnant
50/94 Both Not on OST 6 VL
Strathdee
1998/1999
1996–1997 Vancouver,
Canada
VIDUS cohort: Self-referral,
street outreach
Injected drugs in past month;
resident in Vancouver
region
40/177 MMT Not enrolled in
MMT
11 Cov
Tapp 2011 1996–2008 Vancouver,
Canada
ACCESS cohort: Self-referral,
street outreach
Age >18, illicit drug use other
than cannabinoids in past
month
169/545 MMT Not on MMT 24 AD
Ti 2014 1996–2012 Vancouver,
Canada
ACCESS cohort: Self-referral,
street outreach
Age >18, illicit drug use other
than cannabinoids in past
month
211/587 MMT Not on MMT; 76%
IDU overall
32 VL
Turner 2001 1996–1998 New York
State, USA
Surveillance data of Medicaid
records
Age >18, nonpregnant
women with a live-born
delivery within 5 y
255/412 MMT Illicit drug use in
past 6 mo
CS Coverage
Uhlmann 2010 1996–2008 Vancouver,
Canada
ACCESS cohort: Self-referral,
street outreach
Injected drugs in past month;
resident in Vancouver
region
55/231 MMT Not on MMT in
past 6 mo
24 UP
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analyses to explore potential sources of heterogeneity, including a
priori the method of outcome measurement for adherence, me-
dian length of follow-up or time on ART if available, and propor-
tion of active PWID in the comparison group.
Univariable and multivariable meta-regression analyses were
performed: Time on ART or median follow-up time were in-
cluded a priori in multivariable models, and any variables
from the univariable analysis with P ≤ .20. Those variables
that remained P≤ .05 were retained in the ﬁnal model. Meta-re-
gression was performed using Stata software version 13.0. For
those outcomes with fewer eligible studies, subgroup analyses
were performed to compare summary effects. We assessed the
risk of bias of each study for each included outcome against
different domains, using recommended criteria [23]. Studies
were judged as having low, high, or unclear risk of bias for
each domain.
RESULTS
Search Results
The searches identiﬁed 4685 records, 3558 of which were not du-
plicates (Supplementary Figure 1), with 32 meeting the inclusion
criteria (Table 1). This included 36 327 participants in 19 cohorts
from9 countries. Themedian numberof PWIDper studywas 294
(range, 28–23 813), and the median follow-up period was 24
months (range, 4–104 months) for longitudinal studies (n = 24).
Few studies were from lower-income countries, mainly Asia.
Table 1 continued.
Author and Year
Study
Perioda
Location
(City, Country)
Cohort: Recruitment Site and
Method, Inclusion Criteria
No. on OST/
Total (no./No.)
Type of
OST
Comparison
Population
Median
Follow-
up, mo
ART
Outcomes
Usukula 2012 2010 Tartu, Estonia Hospital clinic recruitment
Age >18, receiving ART, ever
PWID, 33% report illicit DU
in past year overall
66/92 MMT Ever IDU CS AD
Vallecillo 2010 1997–2007 Barcelona,
Spain
Referral to hospital
detoxification units from
outpatient clinics
Age >18, DSM-IV OD with
relapse or severe addiction
380/673 MMT Not on MMT at
admission; 68%
active IDUs
overall at
admission
CS Cov
Vlahov 2005 1996–2002 Baltimore, USA ALIVE cohort: Community
outreach
Age >18, injected drugs
between 1977 and study
entry, ≥1 visit with CD4
count < 200; 40% IDU in
past 6 mo overall
77/295 MMT No MMT in past
6 mo
26 MO
Weber 2009 1997–2006 Multiple,
Switzerland
SHCS cohort: Referral from
outpatient clinics of 7
hospitals
≥2 biannual cohort visits
during study period and
CD4 count and HIV-1 RNA
measured at baseline visit
1348/1489 Both Active IDU in the
past 6 mo
65 Cov VL AT
MO
Westergaard
2013
1998–2011 Baltimore, USA ALIVE cohort: Drug abuse
treatment centers, STD &
HIV clinics, parole officers,
street outreach
Age >18, injected drugs
between 1977 and study
entry, attended ≥2 study
visits
165/740 MMT No MMT in past
6 mo
104 VL
Wood 2005 1996–2003 Vancouver,
Canada
BART cohort: Self-referral,
street outreach
Injected drugs in past month;
resident in Vancouver
region, never on ART at
baseline
171 234 MMT Not on MMT at
baseline
24 UP
Zhao 2013 2002–2011 China Enrollment in China’s national
ART program
Infected through injecting
drug use and starting ART
during the study period
5161/23813 MMT No MMT at any
time while on
ART
21 AT MO
All references are available in the Supplementary Appendix.
Abbreviations: AD, adherence; ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; AT, treatment discontinuation/attrition; BUP, buprenorphine;
CD4, CD4 cell count response to ART; Cov, ART coverage; CS, cross-sectional; DMT, drug maintenance therapy including OST; DSM-IV, Diagnostic and Statistical Manual of Mental
Disorders, 4th Edition; DU, drug use; HIV, human immunodeficiency virus; ICD-9, International Classification of Diseases, Ninth Revision; IDU, injecting drug use; MMT, methadone
maintenance therapy; MO, mortality; NS, not specified within the text; NX, naloxone; OD, opioid dependence; OI, opportunistic infection; OST, opioid substitution therapy; PI, protease
inhibitor; PWID, people who inject drugs; STD, sexually transmitted disease; UP, ART uptake; VL, viral load suppression.
a If the end year of the study is not reported, it was assumed to be 2 years earlier.
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Coverage and Recruitment Onto ART
Ten studies reported on ART coverage, including 3 cross-
sectional studies, 1 case-control study, 4 longitudinal studies,
and 2 surveillance studies presenting coverage at baseline or a
ﬁxed time point (Supplementary Table 1). OST use was associ-
ated with a 54% increase in the odds of being on ART (OR, 1.54;
95% CI, 1.17–2.03; P = .002; Figure 1; Supplementary Table 2)
with moderate heterogeneity (I2 = 67%; P = .001). In the
meta-regression analysis, 28% of the between-study variance
was explained by the different regions (North America vs
Europe), with a larger effect in North America (OR, 1.84;
95% CI, 1.40–2.43; I2 = 37%) than Europe (OR, 1.19; 95%
CI, .75–1.88; I2 = 74%).
Estimates of recruitment onto ART were provided by 4 stud-
ies, with follow-up time ranging from 12 to 42 months (Supple-
mentary Figure 2; Supplementary Table 1). Three other studies
were excluded: 1 duplicate, 1 for only providing a time ratio, and
1 for providing results as an OR that could not be converted to
an HR. All excluded studies found a positive effect of OST on
ART initiation. The pooled estimate for the effect of OSTwas an
87% increase (HR, 1.87; 95% CI, 1.50–2.33; P < .001) in ART
uptake, with no heterogeneity (I2 = 0%; P = .55). There was no
difference in the pooled estimate if a study where inactive PWID
were the comparator was removed.
ART Adherence
Five studies reported on the effect of OST on adherence
(Figure 2; Supplementary Table 3). Only 2 studies used an ob-
jective measure of adherence (pharmacy reﬁlls), whereas others
used self-report, with adherence thresholds ranging from 80%
to 100% of doses. In the pooled estimate, OST use was associ-
ated with a 2-fold increase in adherence (OR, 2.14; 95% CI, 1.41–
3.26; P < .001), with high between-study heterogeneity (I2 = 74%;
P = .004). In a subgroup analysis, the effect was higher for studies
using self-reported adherence (OR, 2.86; 95% CI, 1.35–6.04;
n = 3) compared with using pharmacy reﬁll (OR, 1.88; 95%
CI, 1.11–3.17; n = 2), although both the latter studies were
from Vancouver. In other subgroup analyses, there was no effect
of the adherence threshold, proportion of females in the study,
or geographical region.
Viral Suppression
Ten studies were included that described the impact of
OST on viral suppression (detection threshold being 500, 400,
or 50 copies/mL; Figure 3; Supplementary Table 4). Three studies
Figure 1. Forest plot of the effect of opioid substitution therapy on coverage of antiretroviral therapy (ART) among people who inject drugs (PWID), defined as the proportion
of PWID on ART at a given time point. I2 and P value are measures of between-study heterogeneity. Abbreviations: CI, confidence interval; N, total sample size of PWID;
OR, odds ratio.
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were excluded due to presenting time to viral suppression, where
an ORcould not be calculated, 1 for presenting the impact on viral
loads as a continuous outcome, 3 for being duplicate cohorts, and
1 for presenting the number of visits with suppressed viral loads.
The use of OST was associated with a 45% increase in the odds of
viral suppression (OR, 1.45; 95% CI, 1.21–1.73; P < .001). The re-
sults were fairly homogeneous (I2 = 22%; P = .24).
Increase in CD4 Count
Information on CD4 count gains following ART initiation was
available for 4 studies (Supplementary Table 5). The association
of OST with increases in CD4 count was difﬁcult to assess be-
cause duration of follow-up varied between studies. For 2 stud-
ies, the median increase was marginally smaller in those on OST
at 4 months (79 vs 111 cells/mm3) and 6 months (39 vs 44 cells/
mm3) following ART initiation, compared with those off OST.
However, the increase was substantially larger for those on
OST at 12 months in the latter study and another study
(65 vs 14 cells/mm3 and 46 vs 1 cell/mm3). At 58 months, 1
study found more patients on OST had achieved immune res-
toration (gain of >100 cells/mm3) than those not on OST.
Attrition or Treatment Discontinuation
There were 7 eligible studies describing ART discontinuation/
attrition (Supplementary Table 6). The average time on ART
exceeded 12 months for all 5 studies reporting it. The pooled
estimate found a 23% reduction in the odds of ART discontin-
uation if on OST (OR, 0.77; 95% CI, .63–.95; P = .01) with mod-
erate heterogeneity (I2 = 59%; P = .02; Figure 4). There was no
signiﬁcant difference in effect by sex, duration of ART, or
when studies with inactive PWID were removed.
Mortality
Six studies were included in the analysis of the impact of OST
on mortality while on ART (Supplementary Figure 3; Supple-
mentary Table 7). Only 1 study presented the impact on
HIV-related mortality. There was no evidence for a reduction
in all-cause mortality rates among those on OST while on
ART (HR, 0.91; 95% CI, .65–1.25; P = .55) compared to those
just on ART, although there was substantial heterogeneity
(I2 = 74%; P = .002). The study reporting HIV-related mortality
had comparable results. In a subgroup analysis, OST had a
larger effect on mortality in 2 Asian studies (HR, 0.63; 95%
CI, .57–.70; n = 2) than non-Asian studies (HR, 1.04; 95%
CI, .77–1.40; n = 4). However, the Asian studies had fewer female
participants and shorter follow-up than non-Asian studies.
Publication Bias
Some studies were judged to be at high risk of selection bias, for
instance, due to poor representativeness if the cohorts consisted
Figure 2. Forest plot of the effect of opioid substitution therapy on adherence to antiretroviral therapy (ART) among people who inject drugs (PWID), defined as the proportion
achieving a defined threshold of ART adherence, whether self-reported or objectively measured. I2 and P value are measures of between-study heterogeneity. Abbreviations: CI,
confidence interval; measure, method of measurement of adherence; N, total sample size of PWID; OR, odds ratio; threshold, percentage of doses taken to indicate adherence.
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of volunteers, or if they did not ensure the outcomes were not
present before exposure to OST (Supplementary Table 8). Some
studies did not adjust for known confounders; thus, the results
could be biased in terms of comparability of cohorts. However,
sensitivity analyses limited to adjusted estimates did not sub-
stantially alter our results. Last, some studies had a high risk
of bias due to their method of outcome assessment, mainly
due to the outcome being self-reported or the study not ac-
counting for differential loss to follow-up.
DISCUSSION
This is the ﬁrst systematic review and meta-analysis summariz-
ing evidence on the effect of OST, or MAT, on ART outcomes
among PWID living with HIV. We found strong evidence of a
positive impact on most outcomes: OST increased the coverage
of ART by 54%, recruitment onto ART by 87%, ART adherence
2-fold, viral suppression by 45%, and reduced ART discontinu-
ation by 23%. There was weak evidence that OST improves CD4
count gains, with greater beneﬁts at ≥12 months, and little ev-
idence of OST improving mortality among PWID on ART, al-
though the results had considerable heterogeneity. Despite data
being limited, there was little evidence that the effects of OST on
ART outcomes varied by geographic region, except for ART
coverage, where OST was associated with higher ART coverage
in North America than in Europe, and mortality, which was re-
duced among those on OST in Asia but not elsewhere. There
were insufﬁcient studies to examine other geographical regions.
These ﬁndings support a strong policy recommendation to pro-
vide integrated OST and ART care to PWID to improve individ-
ual clinical beneﬁts, and the potential beneﬁt of HIV treatment
as prevention in this group.
The lack of observed impact on mortality in North America
and Europe is likely due to the small number of studies. Several
studies have shown that OST reduces mortality among PWID
independent of ART [24, 25],mainly as a result of reducing opi-
ate overdose [26, 27]. A more recent study from Vancouver
found that OST conferred additional beneﬁts to ART in re-
ducing both all-cause and HIV-related mortality [28]. This
study beneﬁted from linkage to relevant outcomes through a
provincial database, thereby capturing more events accurately
and providing more rigor to the mortality outcome, which is
particularly vulnerable to attrition bias.
Figure 3. Forest plot of the effect of opioid substitution therapy on plasma viral suppression among people who inject drugs (PWID) on antiretroviral therapy (ART), defined as
the proportion of those on ART with undetectable plasma human immunodeficiency virus (HIV) RNA loads, based on the threshold of detection in each study (<500, <400 or <50
copies/mL). I2 and P value are measures of between-study heterogeneity. Note that Roux used multiple thresholds depending on clinical site. Abbreviations: CI, confidence
interval; N, total sample size of PWID; OR, odds ratio; threshold, number of HIV-1 RNA copies/mL used as threshold for HIV-1 RNA detection in that study.
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As the studies included in this review are observational, it
is possible that there were differences between the populations
on and off OST that could partially explain differences in
outcomes. Unfortunately, few studies presented relevant partic-
ipant characteristics, such as sex, mental illness, alcohol use, or
homelessness stratiﬁed by OST status, which made it difﬁcult to
assess whether these characteristics contributed to the observed
effects. Studies have shown that PWID on OST are considered
by practitioners to be more engaged and reliable than active
PWID not on OST [29, 30]. It is possible that the increased up-
take and coverage of ART in PWID on OST may result from
practitioners’ increased willingness to recruit them into HIV
care [31]. Although improved adherence and viral suppression
might reﬂect a more motivated patient, and may not be due to
the assumed beneﬁts of OST in reducing injecting drug use, a
recent study using linked population-level data found that much
of the improvement in adherence could be attributed to OST
[32, 33]. It is also likely that integration of ART into OST
care increases ART access for those on OST through increased
convenience and reduced out-of-pocket costs, while those not
on OST face additional challenges in navigating HIV care sys-
tems (A. Guise et al, unpublished data).
The limitations of this review include its dependence on a small
number of studies for some outcomes, which reduced our ability
to conduct meta-regression analyses to determine factors contrib-
uting to heterogeneity in our outcomes, and to control for poten-
tial confounding variables. We instead focused on measurable
study characteristics and their associations with effect estimates.
In addition, only comparative studies were included in our review;
this was done to reduce the heterogeneity that would result from
comparing ART outcomes across different populations.
Limited data came from 6 key countries (Ukraine, Russia,
Vietnam, Malaysia, the United States, and China) that contain
50% of all PWID [34, 35], despite not limiting our search by
language or publication source. Furthermore, except for Indo-
nesia and China, all studies were conducted in high-income set-
tings. Estimates depended greatly on a few cohorts of PWID,
likely skewing the data toward those particular settings. This
is especially relevant given that the context in which OST is
delivered is likely to vary and could affect the beneﬁts of OST.
Unfortunately, few studies included details of how OST and
ART were provided. This emphasizes the need for further stud-
ies in lower- or middle-income countries, including models of
integrated care, and how to optimize potential beneﬁts by
Figure 4. Forest plot of the effect of opioid substitution therapy on antiretroviral therapy (ART) discontinuation or attrition among people who inject drugs (PWID), defined as
the proportion of those on ART who were lost to follow-up or discontinued ART during follow-up. I2 and P value are measures of between-study heterogeneity. Abbreviations:
CI, confidence interval; N, total sample size of PWID; OR, odds ratio; time on ART, average time on ART for study participants.
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co-locating ART and OST services, mitigating both drug use
and HIV stigma, and reorienting OST and ART care philoso-
phies to be more client-centered (Guise et al, unpublished data).
In conclusion, this systematic review found strong evidence
to support the use of OST and its inclusion in routine HIV
care for improving the treatment and care continuum among
HIV-infected PWID. It supports the need for policy and health
system reforms to accelerate the integration of OST and HIV
treatment services. The review provides evidence for the multi-
ple potential beneﬁts of OST, and its pivotal importance in a
combination approach to harm reduction [36]. This is particu-
larly important for those countries with a signiﬁcant or increas-
ing prevalence of injecting drug use, and policy restrictions
limiting expansion of harm reduction interventions [37, 38].
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